International Murex Technologies Corp. (AMEX:MXX; TSE) hasgranted Abbott Laboratories (NYSE:ABT) a non-exclusive license toMurex's patented technique for improving immunoassay accuracy.Abbott, of Abbott Park, Ill., will pay Murex a minimum of $10 millionin license fees and royalties over the next four years. Of this amount,Murex, based in Norcross, Ga., will receive $4 million in cash thisyear.The technology pertains to the use of certain antigens in immunoassaykits to improve assay specificity, particularly for the detection ofinfectious agents. _ Philippa Maister
(c) 1997 American Health Consultants. All rights reserved.